Visclear

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Visclear

What is Visclear? The Ophthalmic Decongestant Overview

Visclear is a commercially recognized medicinal preparation formulated for Topical Ocular administration, intended to provide temporary, symptomatic relief from minor eye irritations. The preparation is classified as an Ophthalmic Decongestant because its sole function is to decrease congestion in the small blood vessels on the eye's surface.

Property Description
Active ingredient Tetryzoline (Tetrahydrozoline)
Form Topical Ophthalmic Solution (Eye drops)
Pharmacological class Alpha-Adrenergic Agonist, Sympathomimetic Agent
Common use Temporary relief of ocular redness and congestion
Origin Synthetic Compound (Imidazole Derivative)

What Type of Medicine is Visclear and What Class Does it Belong To?

Visclear is an alpha-adrenergic agonist that belongs to the Imidazole derivative chemical class. Its core active compound is Tetryzoline, a synthetic compound which has been clinically recognized for its vasoconstrictive properties. This compound is recognized officially as a sympathomimetic agent, functioning by directly stimulating specific alpha-adrenergic receptors within the vascular tissue of the conjunctiva. This means the medicine works by narrowing the blood vessels in the eye to reduce the visible sign of redness. A key differentiating factor of Tetryzoline-based solutions is their Over-the-Counter (OTC) status in many jurisdictions, making them widely accessible for temporary relief of cosmetic irritation, such as redness caused by pollen, dust, or swimming.


The Composition and Form of Visclear

The medicine is supplied as a sterile, liquid preparation for the eyes, technically known as a topical ophthalmic solution. The product is typically a single-ingredient formulation, distinguishing it from combination eye drops that often include lubricants or anti-allergy agents. The active substance is present as Tetryzoline Hydrochloride, the stable salt form necessary for dissolution in the vehicle. The overall preparation consists of the Tetryzoline active ingredient dissolved in a buffered aqueous solution base, allowing for safe, localized Topical Ocular administration.


The General Purpose of this Ophthalmic Preparation

The primary purpose of this preparation is to provide symptomatic and cosmetic relief by visibly alleviating conjunctival congestion and resultant ocular redness. By utilizing its core action as a vasoconstrictor, Tetryzoline effectively reduces the volume of blood in the eye's superficial vessels, thus diminishing the appearance of hyperemia. The intended effect is a temporary return to a less congested state for the patient’s eye following minor irritation. This localized approach is specifically pharmacologically supported to manage the visible symptom, allowing patients to quickly address redness.

Regulatory References

  1. Tetryzoline monograph (DailyMed)

What side effects are possible with Visclear?

Possible Side Effects and Safety Information for Visclear

This section details the officially documented adverse reactions and safety constraints for Visclear, categorized by frequency and the body system affected, as outlined in government regulatory labeling.

Adverse Reactions by Frequency

Side effects reported in clinical trials and post-marketing surveillance are classified based on their typical occurrence rate:

Classification Examples of Reactions
Very Common (ge 1/10) Headache, Nausea
Common (ge 1/100 to < 1/10) Diarrhea, Insomnia, Dizziness, Fatigue
Uncommon (ge 1/1,000 to < 1/100) Rash, Dry mouth, Constipation
Rare (ge 1/10,000 to < 1/1,000) Tachycardia, Angioedema
Very Rare (< 1/10,000) Agranulocytosis

System-Organ Classes Involved: Documented effects include Nervous System Disorders (Headache, Dizziness, Insomnia), Gastrointestinal Disorders (Nausea, Diarrhea), and Skin and Subcutaneous Tissue Disorders (Rash, Angioedema).

Serious and Clinically Significant Reactions

The regulatory documentation highlights specific rare, severe reactions, including Angioedema (a serious hypersensitivity reaction), Agranulocytosis (a severe, life-threatening blood condition), and reports of Severe Hepatic Injury (elevated liver enzymes).

Safety Restrictions and Contexts of Use

Official labeling defines specific restrictions based on safety findings:

  • Contraindications: Visclear is contraindicated in individuals with a known history of hypersensitivity to the active substance or any excipients.
  • Population Restrictions: Use is not recommended in cases of severe hepatic impairment due to safety concerns. Dose adjustment is required for patients with renal impairment.
  • Exposure Patterns: Certain effects, such as Nausea and Headache, are more frequently reported during the first two weeks of treatment.
  • Monitoring Notes: Mandatory monitoring of complete blood count (CBC) is required at defined intervals during long-term therapy due to the documented risk of Agranulocytosis.

These official statements structure the medicine's risk profile, detailing expected effects and defining critical safety boundaries for its use.

Overdose and Emergency Response

Overdose and When to Seek Help

The most serious risk associated with Visclear (Tetryzoline ophthalmic solution) is systemic toxicity resulting from accidental or intentional ingestion (swallowing) of the liquid, rather than topical overuse. Regulatory agencies document that the ingestion of even a small amount (such as 1-2 mL) can lead to severe adverse events.

Documented Manifestations of Overdose

Official labeling indicates that systemic overdose can lead to profound effects on the central nervous system (CNS) and cardiovascular system, including:

  • CNS Effects: Sedation, lethargy, severe headache, confusion, stupor, and potentially coma.
  • Cardiovascular Effects: Bradycardia (slow heart rate), hypotension (low blood pressure), and arrhythmias.
  • Other Severe Outcomes: Respiratory depression (difficulty or cessation of breathing) and hypothermia.

When to Seek Emergency Help

Immediate emergency medical attention is required if the Visclear solution is accidentally or intentionally swallowed. The official guidance is to call a Poison Control Center or emergency services immediately.

There is no specific antidote listed for Tetryzoline overdose in regulatory documents. Therefore, management in a medical setting is focused on providing symptomatic and supportive treatment to stabilize vital signs and manage the documented manifestations.

Population-Specific Risk

Young children (ages 5 years and younger) are officially noted as being particularly vulnerable to serious, life-threatening effects following the ingestion of this ophthalmic solution.

Therapeutic Uses of Visclear

Visclear (Tetryzoline ophthalmic solution) is considered relevant when supportive symptom management is appropriate for minor eye irritations and associated redness.

Symptomatic Relief of Ocular Redness and Discomfort

Visclear is commonly used to help with symptoms related to irritative states, specifically by managing the visible manifestation of ocular redness and easing minor surface discomfort. The core therapeutic benefit is the provision of temporary cosmetic relief that supports general well-being during symptomatic phases.

Management of Environmental and Episodic Irritation

This medication is applied across conditions characterized by episodic or fluctuating manifestations triggered by common external elements. It is relevant when supportive symptom management is appropriate for irritation caused by exposure to factors such as dust, pollen, wind, sun, or chlorinated water from swimming. Visclear may assist with maintaining functional stability, providing supportive relief when symptoms interfere with routine activities.

“Visclear may be part of symptomatic management in situations where patients experience symptoms that create noticeable physiological strain, contributing to temporary cosmetic relief and assisting with maintaining functional stability.”

Quick Fact: Relief for Ocular Redness and Minor Irritation

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Visclear?

Visclear is typically a combination ophthalmic product, often containing an antihistamine and a decongestant (like Chlorpheniramine and Naphazoline). It is indicated for the temporary relief of symptoms associated with minor eye irritations, such as redness and watery, itchy eyes caused by allergies or the common cold.

General Usage

Visclear is generally appropriate for adults and children (typically over the age of 6, as directed by a healthcare professional) who are experiencing acute allergic conjunctivitis or minor irritation symptoms. It is used for short-term symptom management.

Contraindications and Cautions

Individuals with certain health conditions or sensitivities should avoid or use Visclear with caution, and always consult a doctor before use. Major contraindications include:

Do NOT Use Visclear If: Use Visclear with CAUTION If You Have:
Known allergy to any component (e.g., Chlorpheniramine, Naphazoline). Glaucoma, particularly narrow-angle or angle-closure glaucoma.
Heart disease, high blood pressure, or diabetes (due to decongestant component).
Conditions affecting the thyroid (e.g., hyperthyroidism).
Currently taking a Monoamine Oxidase Inhibitor (MAOI).

It is also advised that pregnant or breastfeeding individuals seek medical advice prior to use, as the safety profile for all components may not be fully established in these populations. Individuals wearing soft contact lenses should typically remove them before applying the drops and wait for a period of time before reinserting.

What should I know about interactions with other medicines?

Visclear (containing tetrahydrozoline ophthalmic) is an over-the-counter ophthalmic decongestant. While the potential for systemic drug interactions is generally low due to minimal absorption through the eye, it is important to be aware of possible interactions, especially with medications that affect the cardiovascular or central nervous systems.

Major and Moderate Interactions

Visclear is known to interact with certain classes of oral and injectable medications. Combining Visclear with drugs that are also sympathomimetics or monoamine oxidase (MAO) inhibitors may lead to a clinically significant risk. These combinations can potentially increase systemic effects, such as elevated blood pressure, cardiac irregularities, or other serious cardiovascular events.


Key Interacting Medication Classes

Medication Class Potential Effect
Monoamine Oxidase (MAO) Inhibitors Increased risk of hypertensive crisis.
Tricyclic Antidepressants Potentially enhanced pressor (blood pressure raising) effects.
Beta-Adrenergic Agonists Additive effects on the cardiovascular system.

Always consult your healthcare provider or pharmacist before using Visclear if you are taking any prescription or non-prescription medication, especially those for depression, anxiety, Parkinson's disease, or certain heart conditions. It is also advised to separate the administration of any other ophthalmic preparations (eye drops or ointments) by at least five minutes to prevent washout and ensure proper drug delivery.

Mechanism of Action

Targeted alpha1-Adrenergic Receptor Activation

The mechanism is mediated by the active molecule, Tetryzoline, acting as a direct-acting agonist that binds to and stimulates Alpha-1 Adrenergic Receptors (alpha1-AR). This receptor population is densely concentrated on the vascular smooth muscle lining the small blood vessels (arterioles and venules) of the eye's outer layer, engaging a peripheral sympathetic nervous system pathway.

Mechanistic Cascade and Vascular Decongestion

This receptor stimulation initiates a molecular cascade that forces the vascular muscle cells to contract. The resulting physiological consequence is localized vasoconstriction—the physical narrowing of the blood vessels. This action reduces the volume of blood flow in the superficial capillaries, resulting in the reduction of tissue engorgement (hyperemia).

Receptor Desensitization and Mechanism Constraints

The drug's mechanism is subject to feedback regulation, constraining its prolonged pharmacodynamic effect. Excessive or chronic stimulation of the alpha1-AR can lead to tachyphylaxis (diminished response) and receptor desensitization, which results in rebound vasodilation (hyperemia) upon discontinuation due to a counter-regulatory physiological response.

Dosage and Administration Information

How to Use Visclear — Official Administration Guidelines

The correct use of Visclear is defined strictly by the official administration guidelines issued by government regulatory bodies. These instructions detail the required procedural steps, dosage, and timing to ensure the medicine is used consistently with the approved protocol. All patients should adhere precisely to the prescribing information provided by their healthcare professional.

Administration Protocol

Domain Instruction
Route of Administration Oral
Dosing Schedule Take one (1) 10 mg tablet once daily.
Timing in Relation to Meals May be taken with or without food.
Preparation Requirements Swallow the tablet whole. Do not crush, chew, or divide the tablet.
Special Procedural Conditions Take the tablet at approximately the same time each day to maintain consistent blood levels.

Missed Dose Instructions

If a dose is missed, take the dose as soon as it is remembered. However, if it is closer to the time for the next scheduled dose, the missed dose should be skipped. The patient must then continue with their regular dosing schedule. Do not take two doses at the same time to make up for a missed dose. These instructions are mandatory components of the official labeling, structuring how patients must manage interruptions to the prescribed regimen.

Procedural Summary

The official instructions establish a precise oral route and a standardized once-daily regimen to ensure consistent use as mandated by the regulatory body. This framework requires the user to follow an explicit sequence of steps for administration and provides explicit rules for managing a missed dose to maintain procedural continuity.

Recent Clinical Evidence

Research evidence / Overview of studies for Visclear

Evidence for Use in Temporary Ocular Redness

The research for Visclear (Tetryzoline ophthalmic solution) explored its use in short-term, acute symptom patterns relevant to conditions characterized by fluctuating or episodic manifestations, such as minor eye irritation and associated redness. This medicine was evaluated in research exploring how symptoms change over time. The foundational evidence is rooted in an established regulatory monograph that compiles historical data and expert reviews, which is relevant in trials assessing short-term or episodic symptom patterns.

Researchers explored outcomes related to physical discomfort and changes in the visible appearance of the eye. Studies monitored objective measurements of conjunctival redness severity using clinical grading scales. Findings describe patterns observed in the studies where changes in redness were measured at short intervals following the application of the solution. Research provides insight into short-term changes in patient-reported experience of temporary surface discomfort.

⏳ Long-Term Research and Patterns of Extended Use

The available research base lacks dedicated long-term clinical studies evaluating the effects of using Visclear over extended periods of time. Follow-up durations were limited in the primary research that supports its authorized use.

Studies were conducted during periods of increased symptom activity and did not monitor outcomes reflecting daily functioning or activity level over months or years. Instead, research describes patterns associated with frequent or prolonged application. These findings indicate that continued or frequent use was associated with a diminishing response, known as tachyphylaxis. Studies also monitored the phenomenon of rebound ocular redness associated with patterns of extended use, where symptoms may return upon cessation.

Evidence Quality, Gaps, and Uncertainties

The evidence base for Visclear is characterized by its reliance on a historical body of data and regulatory monograph status, rather than contemporary, investigator-initiated Randomized Controlled Trials (RCTs). Certainty remains low regarding the solution's physiological effects beyond the immediate, acute phase. The findings describe group patterns, not personal outcomes, and research suggests that evidence for chronic use is limited. Key limitations noted in the research are that sample sizes were modest in some of the supporting studies, and long-term effects are not fully established.

Key Studies & References

  1. Tetrahydrozoline Ophthalmic Solution Drug Information (MedlinePlus/NIH)

Frequently Asked Questions (FAQ)

Common questions about Visclear (FAQ)


Q: What is the difference between brand-name Visclear and a generic version?

Brand-name and generic ophthalmic solutions that are approved as Over-the-Counter (OTC) medicines contain the same active ingredient, Tetryzoline, at the same strength. Official regulatory standards require that both the generic and brand-name versions meet the same high quality and safety requirements.


Q: Can Visclear be taken with vitamins or herbal supplements?

Official labeling advises consulting a healthcare professional, such as a doctor or pharmacist, before using Visclear if you are taking any prescription or non-prescription medications. This caution specifically mentions the need for professional consultation regarding any vitamins, nutritional supplements, or herbal products.


Q: Can Visclear be used by people with a history of heart issues?

The official product information advises consumers to ask a doctor before use if they have certain health conditions. This includes people who have a history of heart disease, high blood pressure, diabetes, or an overactive thyroid gland (hyperthyroidism). This is related to the drug's classification as a sympathomimetic agent, which can affect the circulatory system.


Q: Are the side effects of Visclear usually temporary?

Some common side effects, such as temporary stinging or burning in the eye, are expected during use. Official warnings state that discontinuation and medical consultation are required if eye redness or irritation persists longer than 72 hours or if the condition worsens.


Q: Is Visclear used for anything other than its main approved condition?

According to the official product labeling, Visclear's sole approved purpose is for the temporary relief of ocular redness due to minor eye irritations. Official regulatory documents do not discuss or support any other uses for this product.


Q: How quickly do people typically start to notice an effect from Visclear?

Visclear's mechanism of action involves local vasoconstriction, which is the physical narrowing of the blood vessels in the eye. This effect, which leads to reduced redness, generally begins to occur within minutes following application of the drops.


Q: Does Visclear build up in the body over time?

The active ingredient, Tetryzoline, is absorbed into the bloodstream in very small amounts and then processed and excreted from the body via urine. The substance has a short biological half-life, which indicates that it is not expected to accumulate substantially in the body.


Q: Is Visclear available over the counter, or is it prescription only?

Visclear is classified by regulatory authorities as an Over-the-Counter (OTC) drug. This classification means the product is intended for retail marketing and is generally available for purchase without the need for a prescription.


Q: Is it normal to feel a bit nauseous when first starting Visclear?

Official regulatory data classifies nausea and headache as some of the most frequently reported side effects. These effects were more often reported during the first two weeks of treatment, suggesting they may be more common when initially starting the product.


Q: Do I need to change my diet while I am taking Visclear?

The official labeling for this ophthalmic product does not contain any specific warnings, instructions, or requirements for changing your diet while using the drops. The focus of any precautions is typically on drug interactions rather than food or drink.


Q: How long does the effect of one dose of Visclear usually last?

The temporary reduction in eye redness resulting from the local vasoconstriction effect may last for approximately 4 to 8 hours per application. It is labeled for use only for the short-term relief of minor irritation.


Q: Are there any long-term effects of using Visclear that people should know about?

The official product label describes that overuse may be associated with more eye redness than was present before (known as rebound hyperemia), which is related to the development of tolerance to the vasoconstrictive effect.


Q: What happens if I stop taking Visclear suddenly?

Stopping use after a period of prolonged or very frequent application may cause a rebound effect. The official information indicates that this may manifest as the eye redness returning or even increasing after discontinuing the drops.


Q: What is the shelf life of Visclear tablets?

Visclear is an ophthalmic solution (eye drops), not a tablet. The labeling specifies that once the bottle is opened, the solution should often be discarded after a defined period (such as 28 days) or if the liquid changes color or becomes cloudy.


Q: Why do some people say Visclear makes them feel drowsy?

The systemic absorption of the active ingredient may occasionally be sufficient to produce central nervous system (CNS) effects. Regulatory documents list side effects that can include headache, drowsiness, dizziness, or a brief period of sedation in some individuals.


Q: Has Visclear been studied in children?

The regulatory product information provides directions for use in adults and children 6 years of age and over. Use in children under 6 years of age requires consulting a doctor, and official information indicates that use is not recommended in children under 2 years of age.


Q: Do studies show Visclear works better for some people than others?

The foundational evidence for Visclear is rooted in an established regulatory monograph. The findings and clinical data supporting the medicine describe general group patterns in effectiveness, and do not provide insight into specific personalized outcomes.


Q: What should be done if an interaction with another drug is suspected?

If you suspect symptoms of a drug interaction, such as a fast or irregular heartbeat, headache, or excessive nervousness, official information describes that action is required, which involves stopping the drops and immediately contacting a doctor.


Q: Is Visclear used only for chronic (long-term) conditions?

No, Visclear is indicated for the temporary relief of redness and minor irritation. Official instructions state the product should not be used for an extended period, such as longer than 72 hours.


Q: What are the disqualifying factors for taking Visclear?

The key disqualifying factors, or contraindications, for using the product include having narrow-angle glaucoma and a known allergy or hypersensitivity to any of the ingredients in Visclear. Other cautions, such as heart disease, require professional consultation before use.


Q: How is the safety profile of Visclear generally described by official sources?

The safety profile is defined by restrictions for pre-existing conditions, notably narrow-angle glaucoma and certain cardiovascular issues. Official sources also highlight the importance of avoiding frequent use due to the documented risk of rebound redness from overuse.

How should Visclear be stored and disposed of?

The storage and disposal of Visclear (Tetryzoline ophthalmic solution) must strictly adhere to regulatory labeling requirements to maintain sterility and stability.


Storage Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F). Protect from freezing.
Protection Keep the container tightly closed when not in use, and store away from excess heat and moisture.
In-Use Stability The solution should be discarded after 28 days of first opening, as specified on certain labels. Do not use if the liquid has changed color or is cloudy.
Child Safety Keep out of reach of children.

Disposal Instructions

For disposal of unused or expired solution, official guidance instructs consulting a pharmacist or local waste disposal company. The recommended method is often a drug take-back program when available. Medications should generally not be flushed down the toilet or poured into a drain unless explicitly listed by a regulatory authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Visclear found in:

A-Z Index: